
Assessed for eligibility (n = 35)
Excluded (n = 1)
Failed eligibility criteria (n = 1)
Randomised (n = 34)
Cohort A
(masitinib plus cholinesterase inhibitor and/or memantine)
Cohort B
(placebo plus cholinesterase inhibitor and/or memantine)
Allocated to masitinib-arm (n = 26)
Received allocated intervention (n = 26)
Start dose of 3 mg/kg/day (n = 12)
Start dose of 6 mg/kg/day (n = 14)
Allocated to placebo-arm (n = 8)
Received allocated intervention (n = 8)
Premature discontinuation (n = 17)
Adverse event (n = 9)
Protocol violation (n = 1)
Withdrawal of consent (n = 2)
Investigator death (n = 7)
Premature discontinuation (n = 2)
Adverse event (n = 0)
Protocol violation (n = 1)
Withdrawal of consent (n = 0)
Investigator death (n = 1)
On-going at week 24 (n = 9)
Primary endpoint analysis* (n = 16)
On-going at week 24 (n = 6)
Primary endpoint analysis* (n = 6)
*Week 12 data for closed study centre imputed using LOCF for week 24.